124 related articles for article (PubMed ID: 38368741)
1. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Tarantino P; Ajari O; Graham N; Vincuilla J; Parker T; Hughes ME; Tayob N; Garrido-Castro AC; Morganti S; King TA; Mittendorf EA; Curigliano G; Lin NU; Tolaney SM
Eur J Cancer; 2024 Apr; 201():113920. PubMed ID: 38368741
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
3. Impact of residual disease biomarkers on the prognosis of HER2-positive breast cancer following neoadjuvant therapy.
Ma Y; Zhu M; Lv M; Yuan P; Chen X; Liu Z
Cancer Med; 2023 May; 12(10):11293-11304. PubMed ID: 36951436
[TBL] [Abstract][Full Text] [Related]
4. Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases.
Zhu S; Lu Y; Fei X; Shen K; Chen X
Br J Cancer; 2023 Oct; 129(8):1274-1283. PubMed ID: 37604930
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature.
Mogica JP; Tang H; Liang Y; Zhong M; Hui P; Harigopal M; Krishnamurti U; Fischbach NA; Zhan H
Breast; 2023 Dec; 72():103586. PubMed ID: 37812963
[TBL] [Abstract][Full Text] [Related]
6. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
7. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
8. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
9. Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes.
Wetzel CL; Sutton TL; Gardiner S; Farinola M; Johnson N; Garreau JR
J Surg Oncol; 2021 Dec; 124(8):1224-1234. PubMed ID: 34416025
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
Spring LM; Bar Y; Isakoff SJ
J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
[TBL] [Abstract][Full Text] [Related]
11. Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Denkert C; Lambertini C; Fasching PA; Pogue-Geile KL; Mano MS; Untch M; Wolmark N; Huang CS; Loibl S; Mamounas EP; Geyer CE; Lucas PC; Boulet T; Song C; Lewis GD; Nowicka M; de Haas S; Basik M
Clin Cancer Res; 2023 Apr; 29(8):1569-1581. PubMed ID: 36730339
[TBL] [Abstract][Full Text] [Related]
12. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
13. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract][Full Text] [Related]
15. Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
Peterson JR; Cole JA; Pfeiffer JR; Norris GH; Zhang Y; Lopez-Ramos D; Pandey T; Biancalana M; Esslinger HR; Antony AK; Takiar V
Breast Cancer Res; 2023 May; 25(1):54. PubMed ID: 37165441
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
18. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
[TBL] [Abstract][Full Text] [Related]
20. Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC.
Zheng S; Li L; Chen M; Yang B; Chen J; Liu G; Shao Z; Wu J
Breast; 2022 Jun; 63():177-186. PubMed ID: 35429731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
